Entasis Therapeutics (NASDAQ:ETTX) Downgraded by Zacks Investment Research to Sell

Entasis Therapeutics stock has undergone multiple analysts rating changes in the recent past.  Entasis Therapeutics Downgraded by Zacks Investment Research on 10-12-21. In a note to investors, the firm issued a new rating of Sell. The analysts previously had rating of Hold.

Shares of Entasis Therapeutics traded up $0.11 on Tuesday, reaching $3.26. 0 shares of the stock traded hands, compared to its average volume of 285814. Shares of Entasis Therapeutics were trading at $3.26 on Tuesday. The firm’s 50 day moving average is $2.88 and its 200 day moving average is $2.62.Entasis Therapeutics has a 12 month low of $3.15 and a 12 month high of $3.88. While on yearly highs and lows, Entasis Therapeutics’s today has traded high as $3.27 and has touched $3.15 on the downward trend. See More Analyst Rating at: RATING

Entasis Therapeutics Earnings and What to expect: 

Entasis Therapeutics last announced its quarterly earnings results on August 11th, 2021. The reported ($0.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by $0.05. Entasis Therapeutics has generated ($2.10) earnings per share over the last year (($1.07) diluted earnings per share). Earnings for Entasis Therapeutics are expected to grow in the coming year, from ($1.12) to ($1.04) per share. Entasis Therapeutics has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Thursday, November 4th, 2021 based off prior year’s report dates.

Earnings for Entasis Therapeutics are expected to grow in the coming year, from ($1.12) to ($1.04) per share. The P/E ratio of Entasis Therapeutics is -3.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Entasis Therapeutics is -3.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Entasis Therapeutics has a P/B Ratio of 2.22. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Entasis Therapeutics (NASDAQ:ETTX) Moving Average Technical Analysis

5 day Moving Average is $3.12 And 5 day price change is $0.08 (2.52%)  with average volume for 5 day average is 118,080. While technical analysis for average 20 days shows significant difference, 20 day moving average is  $3.29 and 20 day price change is $0.41 (14.39%) and average 20 day moving volume is 361,315. 50 day moving average is $2.88  and 50 day price change is $0.90 ( 38.14%)  and with average volume for 50 days is : 214,708. 200 day moving average is $2.62  and 200 day price change is $0.41 (14.39%)  and with average volume for 200 days is : 326,051.

Other owners latest trading in Entasis Therapeutics :

  • On 8/17/2021 shares held by Bridgeway Capital Management LLC were 110,000 which equates to market value of $0.29M and appx 0.00% owners of Entasis Therapeutics
  • On 8/16/2021 shares held by Alberta Investment Management Corp were 130,000 which equates to market value of $0.35M and appx 0.00% owners of Entasis Therapeutics
  • On 8/16/2021 shares held by Occudo Quantitative Strategies LP were 23,058 which equates to market value of $62K and appx 0.00% owners of Entasis Therapeutics
  • In total Institutional ownership equates to Institutional Ownership Percentage: 7.04% for Entasis Therapeutics

See More Analyst Rating at: RATING